154 related articles for article (PubMed ID: 20433538)
1. New data on ONTARGET: more confusion?
Escobar C; Echarri R; Barrios V
J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
[No Abstract] [Full Text] [Related]
2. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
3. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
4. Proteinuria: Is the ONTARGET renal substudy actually off target?
Ruggenenti P; Remuzzi G
Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
[No Abstract] [Full Text] [Related]
5. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
Middeke M
Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
[No Abstract] [Full Text] [Related]
6. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
Nilsson PM
Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
[No Abstract] [Full Text] [Related]
7. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
[TBL] [Abstract][Full Text] [Related]
8. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
9. ONTARGET: questions asked, questions answered.
Weber MA
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
[No Abstract] [Full Text] [Related]
10. ONTARGET should not be over interpreted.
Abutaleb N
Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
[No Abstract] [Full Text] [Related]
11. [ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
Düsing R; Nitschmann S
Internist (Berl); 2008 Sep; 49(9):1137-40. PubMed ID: 18665340
[No Abstract] [Full Text] [Related]
12. Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
Wang JG; Pimenta E; Chwallek F
Vasc Health Risk Manag; 2014; 10():189-200. PubMed ID: 24741317
[TBL] [Abstract][Full Text] [Related]
13. Is therapy of people with chronic kidney disease ONTARGET?
Mann JF; Tobe S; Teo KK; Yusuf S
Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
[No Abstract] [Full Text] [Related]
14. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
17. ARBs for cardiovascular and renal protection in high-risk patients.
Aalbers J
Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
[No Abstract] [Full Text] [Related]
18. A third amlodipine/ARB combination (Twynsta) for hypertension.
Med Lett Drugs Ther; 2010 Jan; 52(1329):2-3. PubMed ID: 20208469
[No Abstract] [Full Text] [Related]
19. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan in the treatment of hypertension.
Rosario BH; Hendra TJ
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):485-92. PubMed ID: 18433350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
